{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:42Z","timestamp":1788984822589,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01855-2","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:28:45Z","timestamp":1785432525000},"page":"4599-4616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-2836","authenticated-orcid":false,"given":"Felix","family":"Lauffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kreutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-7799","authenticated-orcid":false,"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Schwichtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5392-8296","authenticated-orcid":false,"given":"Fatima","family":"Abousamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8044-1821","authenticated-orcid":false,"given":"Melanie","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1855_CR1","unstructured":"S3 guideline on atopic dermatitis (AWMF registry number 013\u2013027). 2023. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-027. Accessed Oct. 24, 2025"},{"key":"1855_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"1855_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018. https:\/\/doi.org\/10.1111\/all.13401.","journal-title":"Allergy"},{"key":"1855_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.06.044","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020. https:\/\/doi.org\/10.1016\/j.jaip.2019.06.044.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1855_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.052","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.052.","journal-title":"J Am Acad Dermatol"},{"key":"1855_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15817","author":"YR Woo","year":"2021","unstructured":"Woo YR, Han Y, Lee JH, et al. Real-world prevalence and burden of genital eczema in atopic dermatitis: a multicenter questionnaire-based study. J Dermatol. 2021. https:\/\/doi.org\/10.1111\/1346-8138.15817.","journal-title":"J Dermatol"},{"key":"1855_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1572","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018. https:\/\/doi.org\/10.1001\/jamadermatol.2018.1572.","journal-title":"JAMA Dermatol"},{"key":"1855_CR8","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0011","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults - diagnosis and treatment. Dtsch Arztebl Int. 2023. https:\/\/doi.org\/10.3238\/arztebl.m2023.0011.","journal-title":"Dtsch Arztebl Int"},{"key":"1855_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50507","author":"SU Din","year":"2023","unstructured":"Din SU, Saeed MA, Hameed MR, Aamer M, Arshad U, Qamar HY. Implementation of the treat-to-target approach in psoriatic arthritis and its outcomes in routine clinical practice. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.50507.","journal-title":"Cureus"},{"key":"1855_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152465","author":"Y Hao","year":"2024","unstructured":"Hao Y, Oon S, Nikpour M. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: a systematic review and meta-analysis. Semin Arthritis Rheum. 2024. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152465.","journal-title":"Semin Arthritis Rheum"},{"key":"1855_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20229","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20229.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1855_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01469-0","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Gooderham M, Wollenberg A, et al. Impact of achieving optimal treatment targets and minimal disease activity on health-related quality of life and satisfaction in patients with atopic dermatitis. Dermatol Ther (Heidelb). 2025. https:\/\/doi.org\/10.1007\/s13555-025-01469-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1855_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week\u00a016 results of an open-label randomized efficacy assessor-blinded head-to-head phase\u00a0IIIb\/IV study (Level Up). Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae404.","journal-title":"Br J Dermatol"},{"key":"1855_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021. Erratum in: Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2 (https:\/\/doi.org\/10.1016\/S0140-6736(21)01214-9).","journal-title":"Lancet"},{"key":"1855_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"key":"1855_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.033","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase\u00a03, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023. Erratum in: J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.033 (https:\/\/doi.org\/10.1016\/j.jaad.2023.11.042).","journal-title":"J Am Acad Dermatol"},{"key":"1855_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01373-7","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Schadeck T, Jacobs F, et al. Early achievement of high treatment targets in moderate-to-severe atopic dermatitis with upadacitinib: real-world evidence from the observational UP-TAINED study. Dermatol Ther (Heidelb). 2025. https:\/\/doi.org\/10.1007\/s13555-025-01373-7.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1855_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1560222","author":"C Foley","year":"2019","unstructured":"Foley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2019. https:\/\/doi.org\/10.1080\/03007995.2018.1560222.","journal-title":"Curr Med Res Opin"},{"key":"1855_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08296.x","author":"AW Evers","year":"2008","unstructured":"Evers AW, Duller P, van de Kerkhof PC, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol. 2008. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08296.x.","journal-title":"Br J Dermatol"},{"key":"1855_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2428729","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Calimlim BM, Grada A, et al. Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry. J Dermatolog Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2024.2428729.","journal-title":"J Dermatolog Treat"},{"key":"1855_CR21","unstructured":"Pereyra-Rodriguez JJ, Grewal P, Pezzolo E, et al. Effectiveness and achievement of minimal disease activity with upadacitinib in adults and adolescents with atopic dermatitis: 12-month interim analysis of the real-world multicountry AD-VISE Study. Presented at the European Academy of Dermatology and Venereology (EADV), September 17\u201320, 2025, Paris, France. P0333"},{"key":"1855_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis"},{"key":"1855_CR23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-1162","author":"GH Koc","year":"2025","unstructured":"Koc GH, Kok MR, Snoeck Henkemans SVJ, et al. The effect of early attainment of minimal disease activity on radiographic outcomes: a real-world longitudinal cohort study in psoriatic arthritis. J Rheumatol. 2025. https:\/\/doi.org\/10.3899\/jrheum.2024-1162.","journal-title":"J Rheumatol"},{"key":"1855_CR24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449","author":"L Gossec","year":"2018","unstructured":"Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol. 2018. https:\/\/doi.org\/10.3899\/jrheum.170449.","journal-title":"J Rheumatol"},{"key":"1855_CR25","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/194595","author":"M Bektas","year":"2024","unstructured":"Bektas M, \u00c7elik B, \u0130nce B, et al. Minimal disease activity and associated factors in patients with psoriatic arthritis: cross-sectional study from a single center. Reumatologia. 2024. https:\/\/doi.org\/10.5114\/reum\/194595.","journal-title":"Reumatologia"},{"key":"1855_CR26","unstructured":"Lauffer F, von Kiedrowski R, Quist S, et al. Effectiveness of upadacitinib in moderate vs severe atopic dermatitis: interim results. Presented at the European Academy of Dermatology and Venereology (EADV), September 17\u201320, 2025, Paris, France. P0274"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01855-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:22Z","timestamp":1788981682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01855-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1855"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01855-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Felix Lauffer is a member of advisory boards and\/or a speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, BMS, Janssen, LEO Pharma, Eli Lilly, Novartis, Roche, Sanofi, UCB, Pfizer, and Union Therapeutics. Boris Bauer has served as a consultant, investigator, speaker, or has received grants from AbbVie, Eli Lilly, BMS, Novartis, UCB, Biogen, Sanofi, LEO Pharma, Janssen, Almirall, and Ichthyol-Gesellschaft. Katharina Kreutzer is a member of advisory boards and\/or speaker for AbbVie, Almirall, LEO Pharma, Eli Lilly, Sanofi, Janssen, Medac, Novartis, UCB, and is involved in conducting clinical trials with pharmaceutical drugs developed for inflammatory diseases. Knut Sch\u00e4kel has served as a consultant, investigator, speaker, or has received grants from AbbVie, Amgen, Almirall, Biogen, BMS, Boehringer Ingelheim, Celgene, Chugai, Galderma, Johnson & Johnson, LEO Pharma, Eli Lilly, Merck Sharp & Dohme Corp., Novartis, Pfizer, Regeneron, and UCB. Uwe Schwichtenberg is a member of advisory boards and\/or speaker for AbbVie, Almirall, Amgen, Hautnetz Hamburg, Hexal, Janssen, LEO Pharma, Eli Lilly, MedLearning, Merz, Novartis, RG, Sanofi, UCB, and\u202fis CEO of medical project design GmbH. Johannes Hockmann has received speaking fees and\/or served as investigator for AbbVie, Almirall, BMS, Institut f\u00fcr haus\u00e4rztliche Fortbildung, Janssen, LEO Pharma, Novartis, Pfizer, RG \u00c4rztefortbildung, and Sanofi. Andreas Pinter has been a consultant and advisor and\/or received speaking fees and\/or served as an investigator for the following companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Biontec, BMS, Boehringer Ingelheim, Celgene, Celltrion, GSK, Eli Lilly, Eva\u202fPharma, Galderma, Hexal, Incyte, Janssen-Cilag, Klinge Pharma, LEO Pharma, MC2, Medac, Merck\u202fSerono, Mitsubishi, MoonLake, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough, UCB Pharma, and Z\u00fcllig Pharma. Fatima Abousamra and Melanie Huber are employees of AbbVie and may own AbbVie stock. Stephan Weidinger has received institutional research grants from LEO Pharma, Pfizer, and Sanofi Deutschland GmbH, as well as lecture and\/or consultancy fees from AbbVie, Almirall, Apogee, Astria, Boehringer Ingelheim, Eli Lilly, Galderma, GSK, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the requirements for non-interventional observational studies, no additional diagnostic or monitoring procedures or measurements that would not be feasible for use in routine clinical care were done in this study. Study-related monitoring, if applicable, was permitted by the study sites\/investigators, including audits, independent ethics committee or independent review board appraisal, and regulatory inspection(s). This study was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments. Ethics committee approval was obtained by the medical faculty in Kiel, Germany, on November 1, 2021 (D 598\/21). All participants (or, for adolescent participants, their legal guardians) provided written informed consent prior to enrollment in the UP-TAINED study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}